Non-Hodgkin's B cell lymphomas (NHL) include a diverse set of neoplasms that constitute ∼90% of all lymphomas and the largest subset of blood cancers. While chemotherapy is the first line of treatment, the efficacy of contemporary chemotherapies is hampered by dose-limiting toxicities. Partly due to suboptimal dosing, ∼40% of patients exhibit relapsed or refractory disease. Therefore more efficacious drug delivery systems are urgently needed to improve survival of NHL patients. In this study we demonstrate a new drug delivery platform for NHL based on the plant virus Potato virus X (PVX). We observed a binding affinity of PVX towards malignant B cells. In a metastatic mouse model of NHL, we show that systemically administered PVX home to tissues harboring malignant B cells. When loaded with the chemotherapy monomethyl auristatin (MMAE), the PVX nanocarrier enables effective delivery of MMAE to human B lymphoma cells in a NHL mouse model leading to inhibition of lymphoma growth in vivo and improved survival. Thus, PVX nanoparticle is a promising drug delivery platform for B cell malignancies.

中文翻译：

---

植物病毒纳米粒子马铃薯病毒X（PVX）对恶性B细胞的亲和力可实现癌症药物的递送。

非霍奇金氏B细胞淋巴瘤（NHL）包括多种肿瘤，占所有淋巴瘤的90％，也是血液癌的最大子集。虽然化学疗法是治疗的第一线，但当代化学疗法的疗效受到剂量限制毒性的阻碍。部分由于剂量欠佳，约40％的患者表现出复发或难治性疾病。因此，迫切需要更有效的药物递送系统来提高NHL患者的生存率。在这项研究中，我们展示了一种基于植物病毒马铃薯X病毒（PVX）的NHL新药物递送平台。我们观察到PVX对恶性B细胞的结合亲和力。在NHL的转移性小鼠模型中，我们显示系统地将PVX给药至窝藏有恶性B细胞的组织。当装有化学治疗的单甲基澳他汀（MMAE）时，体内存活率提高。因此，PVX纳米颗粒是B细胞恶性肿瘤的有希望的药物输送平台。